Search

Your search keyword '"Sarmati L"' showing total 607 results

Search Constraints

Start Over You searched for: Author "Sarmati L" Remove constraint Author: "Sarmati L"
607 results on '"Sarmati L"'

Search Results

1. Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

2. Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy

3. Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

4. Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study

5. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

6. Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies

8. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper

9. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis

10. HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV sub-genotypes 1 inducing different inflammatory stimuli

11. Pillars of long-term antiretroviral therapy success

12. Expression profile of HERVs and inflammatory mediators detected in nasal mucosa as a predictive biomarker of COVID-19 severity

13. Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations

14. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro

15. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients

16. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

17. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

18. Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021

19. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis

20. Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals

21. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients

22. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

23. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

24. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

25. Clinical management of imported malaria in Italy: Results from a national cross-sectional survey in 2015

26. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

27. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

28. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

29. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases

30. Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort

31. Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO)

32. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

33. Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO)

34. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

35. Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

36. Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14

37. An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein

42. for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays

45. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis

46. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

47. Whole-brain white matter network reorganization in HIV

48. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia

49. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor

Catalog

Books, media, physical & digital resources